Page 202 - 2021_12-Haematologica-web

Letters to the Editor
Therapeutics, Immunitas Therapeutics, LifeVault Bio, Novartis, Rheos Medicines, Talaris Therapeutics and TScan Therapeutics, outside the submitted work. JK has served as a consultant for Amgen, Equillium, Cugene, and Moderna and advisory board for therakos; and received funding from BMS, Miltenyi, Clinigen, and Regeneron, outside the submitted work. PA has served as a consultant for Merck, BMS, Pfizer, Affimed, Adaptive, Infinity, ADC Therapeutics, Celgene, Morphosys, Daiichi Sankyo, Miltenyi, Tessa, GenMab, C4, and Enterome; received research funding from Merck, BMS, Affimed, Adaptive, Roche, Tensha, Otsuka, Sigma Tau, Genentech, IGM and received honoraria from Merck and BMS, outside the submitted work. RJS has served as a consultant for Gilead, Rheos Therapeutics, Jazz, Cugene, Mana Therapeutics, VOR, and Novartis; served on data safety monitoring committees for Juno; served on board of directors for Kiadis and Be the Match/ NMDP, outside the submitted work. HTK has served as a consultant for Miltenyi, outside the submitted work. The remaining authors declare no competing
financial interests.
Contributions: HTK conceived and designed the study, performed statistical analysis, interpreted the data and wrote the manuscript; JRB, CJW and MD conceived the study; POB and JRB compiled the out- come data, provided FISH data and annotated the cytogenetic data; JRB and JR edited the manuscript. All authors contributed to the manu- script review and approved the final version for submission.
Acknowledgments: we thank the patients and their families, the research coordinators, research nurses, and advanced practice providers.
Funding: this work was supported by research funding from the National Cancer Institute (P01CA229092) and the Ted and Eileen Pasquarello Tissue Bank in Hematologic Malignancies.
References
1. Wang Y, Tschautscher MA, Rabe KG, et al. Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica. 2020;105(3):765-773.
2. Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syn- drome. Blood. 2018;131(25):2761-2772.
3. Allan JN, Furman RR. Current trends in the management of Richter's syndrome. Int J Hematol Oncol. 2019;7(4):IJH09.
4.Kadri S, Lee J, Fitzpatrick C, et al.Clonal evolution underlying
leukemia progression and Richter transformation in patients with
ibrutinib-relapsed CLL. Blood Adv. 2017;1(12):715-727.
5. Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lym-
phocytic leukemia. JAMA Oncol. 2015;1(1):80-87.
6. Jain P, Thompson PA, Keating M, et al. Long-term outcomes for
patients with chronic lymphocytic leukemia who discontinue ibruti-
nib. Cancer. 2017;123(12):2268-2273.
7. Dreger P, Schnaiter A, Zenz T, et al. TP53, SF3B1, and NOTCH1
mutations and outcome of allotransplantation for chronic lympho- cytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood. 2013;121(16):3284-3288.
8. Dreger P, Montserrat E. European Society for Blood and Marrow Transplantation (EBMT); European Research Initiative on CLL (ERIC). Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia? Curr Hematol Malig Rep. 2015;10(1):59-64.
9. Tsimberidou AM, O’Brien S, Khouri I, et al. Clinical outcomes and prognostic factors in patients with Richter’s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006;24(15):2343-2351.
10. Cwynarski K, Van Biezen A, De Wreede L, et al. Autologous and allogeneic stem-cell transplantation for transformed chroniclympho- cytic leukemia (Richter’s syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chroni- cleukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012;30(18):2211-2217.
11. Kharfan-Dabaja MA, Kumar A, Stingo F, et al. Allogeneic hematopoi- etic cell transplantation for richter syndrome: a single-centerexperi- ence.Clin. Lymphoma. Myeloma Leuk. 2018:18(1):e35-e39.
12. Kim HT, Ahn KW, Hu ZH, et al Prognostic score and cytogenetic risk classification for reduced intensity conditioning allogeneic HCT in CLL patients: CIBMTR report. Clin Cancer Res. 2019;25(16):5143- 5155.
13. Kim HT, Shaughnessy CJ, Rai SC, et al. Outcome of high-risk chronic lymphocytic leukemia patients undergoing allogeneic hematopoietic cell transplant after prior targeted therapy. Blood Adv. 2020; 4(17):4113-4123.
14. Fenske T, Ahn K, Graff T, et al. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autol- ogous transplantation. Br J Haematol. 2016;174(2):235-248.
15. Kittai AS, Bond DA, William B, et al. Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome. Blood Adv. 2020; 4(19):4648-4652.
16. Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syn- drome reveals disease heterogeneity and predicts survival after trans- formation. Blood. 2011;117(12):3391-3401.
3222
haematologica | 2021; 106(12)